<!DOCTYPE html>
<!--[if IE 7 ]>    <html lang="en-US" class="ie7"> <![endif]-->
<!--[if IE 8 ]>    <html lang="en-US" class="ie8"> <![endif]-->
<!--[if IE 9 ]>    <html lang="en-US" class="ie9"> <![endif]-->
<!--[if (gt IE 9)|!(IE)]><!--> <html lang="en-US"> <!--<![endif]-->
  
<!-- Mirrored from www.merck.com/clinical-trials/infographics/oncology.html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 18 Feb 2017 23:08:31 GMT -->
<head>
    <meta charset="utf-8">
    <title>Merck Clinical Trials - Oncology</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="">
    <meta name="author" content="">
<!-- Font - UniversLTW01-57Condense 723821 -->
    <link type="text/css" rel="stylesheet" href="../../../fast.fonts.net/cssapi/35024326-4878-4b91-bc05-90e61b3baf52.css"/>
    <link href="../css/bootstrap.css" rel="stylesheet" />
    <link href="../css/docs.css" rel="stylesheet" />
    <link href="../css/inside.css" rel="stylesheet" />
	<link href="../css/superfish.css" rel="stylesheet" media="screen" />
    <link rel="stylesheet" href="../../../code.jquery.com/ui/1.10.3/themes/smoothness/jquery-ui.css" />
    <link href="../css/ie.css" rel="stylesheet" />
    <!-- HTML5 shim, for IE6-8 support of HTML5 elements -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script>
    <![endif]-->
	<style>
		h2 {
			margin: 0 auto;
			padding: 15px 0 7px 0;
		}
		p {
    		margin: 0;
    		padding: 7px 0;
    	}
    	.container .introText {
    		padding-bottom: 35px;
    	}
    	#clear_space {
    		width: 100%;
    		clear: both;
    		float: none;
    		height: 50px;
    	}
		#home4 {
			background-image: url(../images/oncology-top.jpg);
			background-repeat: no-repeat; 
			background-size: 100%; 
			width: 100%; 
			min-height: 397px;
			height: auto;
		}
		.home4content {
			width: 395px;
			display: block;
			left: 20%;
			top: 30px;
			position: relative;
			z-index:8;
		}
		.home4content h1 { font-size: 28px; line-height: 1.2em; color: #bcbdbc; margin-bottom: 15px; }
		.home4content p { font-size: 16px; line-height: 1.5em; color: #37424a; }
		.subhead .container.top {
			height: 50px;
		}
		.subhead .container .span7 h1 {
			margin: 6px 2px 2px 2px;
			padding: 8px;
		}
		#quoteBox {
			background: #00877C;
			color: #FFFFFF;
			padding: 15px;
			float: left;
			line-height: 1.5em;
		}
		#quoteBox p {
			font-size: 25px;
			margin: 0 auto;
			padding: 0;
		}
		#findStudyBox {
			width: 615px;
			padding-top: 15px;
			float: right;
			min-height: 175px;
		}
		#callout {
			margin: -55px 0px 0px 0px;
			padding: 15px 30px;
			float: left;
			background-color: #b9be10;
			-webkit-border-radius: 10px;
			-moz-border-radius: 10px;
			-o-border-radius: 10px;
			border-radius: 10px;
		}
		#filters {
			margin: 0 auto;
			padding: 10px 0px;
			text-align: center;
		}
		#filters button {
			background: #666666;
			border: none;
			color: #FFFFFF;
			padding: 4px 8px;
			-webkit-border-radius: 5px;
			-moz-border-radius: 5px;
			-o-border-radius: 5px;
			border-radius: 5px;
			opacity: 0.8;
			text-transform: uppercase;
		}
		#filters button.is-checked, #filters button:hover {
			background: #333333;
			opacity: 1;
		}
		.grid {
			margin: 0 auto;
			padding: 10px 0px 50px 0px;
		}
		.grid-item {
			position: relative;
			float: left;
			width: 280px;
			height: 295px;
			margin: 5px;
			padding: 10px;
			background: #cce7e5;
			color: #00877c;
		}
		.grid-item--width2 {
			width: 50%;
		}
		.grid-item p, .grid-item--width2 p {
			font-size: 14px;
			line-height: 1em;
		}
		.grid-item .tag {
			position: absolute;
			float: right;
			text-align: right;
			right: 15px;
			font-weight: bold;
			text-transform: uppercase;
			color: #666666;
		}
		.button {
			margin-top:10px;
		}
		#social {
			top: 171px;
			right: 10%;
			position: absolute;
			width:970px;
		}
		#social .share {
			margin: -24px 0px 10px 610px;
			width:200px;
			float: left;
		}
	</style>
  </head>

  <body>
  	<div id="wrap">
		<div class="header_container">
            <div class="container">
                	            	<div class="row">
                	<div class="span4">
                    	<a href="../index.html"><img class="logo" src="../images/clinical_trials_logo.png" alt="Merck Clinical Trials logo" border="0" /></a>
                    </div><!-- End of span4 -->
                	<div class="span8">
                    
<ul class="sf-menu">
   <li><a href="../about-clinical-trials.html">About Clinical <br />Trials</a></li>
   <li><a href="../patients-and-caregivers.html">Patients &amp; <br>
Caregivers</a></li>
   <li><a href="../healthcare-practitioners.html">Healthcare <br>
Practitioners</a></li>	
   <li><a href="../policies-perspectives.html">Policies &<br>
 Perspectives</a></li>
   <li><a href="../frequently-asked-questions.html">Frequently Asked <br />
   Questions</a></li>		
</ul>

                        
                    </div><!-- End of span8 -->
              	</div><!-- End of row -->
            </div><!-- End of container -->
        </div><!-- End of header_container -->
        
        <header class="subhead">

        	<div class="container top">
           		<div class="span7">
           			<h1>MERCK ONCOLOGY CLINICAL TRIALS</h1>
           		</div>
        	</div>           
	           	        <div id="social" class="hidden-print">
	        	
	            <!-- start share buttons -->    
	            <div class="share">
	            
	                <table width="200" border="0" cellspacing="0" cellpadding="0">
	                  <tr>
	                    <td>            
	                			<style> 
	                            .fb_edge_widget_with_comment span.fb_edge_comment_widget iframe.fb_ltr {
	                            display: none !important;} 
	                            
	                            .fb_edge_widget_with_comment { top: -55px; margin-bottom: 10px; }
	                            
	                            .DOMControl_placeholder { display:none; }
	                            </style>
	                            
	                            <!--[if IE 7]>
	                            <style>
	                            .fb_edge_widget_with_comment { margin-top: -25px; }
	                            </style>
	                            <![endif]-->
	                            <!-- FACEBOOK LIKE BUTTON -->
	                                    <div id="fb-root"></div>
	                                    <script>(function(d, s, id) {
	                                    var js, fjs = d.getElementsByTagName(s)[0];
	                                    if (d.getElementById(id)) return;
	                                    js = d.createElement(s); js.id = id;
	                                    js.src = "../../../connect.facebook.net/en_US/all.js#xfbml=1";
	                                    fjs.parentNode.insertBefore(js, fjs);
	                                    }(document, 'script', 'facebook-jssdk'));</script>
	                                    <!-- END OF FACEBOOK LIKE BUTTON -->
	                            
	                                 <!-- FACEBOOK LIKE BUTTON -->
	                                    <div class="fb-like" data-send="false" data-layout="button" data-width="450" data-show-faces="true"  style="vertical-align:top;"></div>
	                                    <!-- END OF FACEBOOK LIKE BUTTON -->
	                    </td>
	                    <td style="padding-top: 5px !important;" >
	                                   &nbsp;&nbsp;<a href="https://twitter.com/share" class="twitter-share-button" data-text="Merck Clinical Trials - About ">Tweet</a>
	                            <script>!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+'://platform.twitter.com/widgets.js';fjs.parentNode.insertBefore(js,fjs);}}(document, 'script', 'twitter-wjs');</script>
	                            
	                    </td>
	                  </tr>
	                </table>                
	            </div> 
	            <!-- end share buttons --> 
	             
	            <div style="width: 160px; float:right; padding-top:0px;">
<ul class="utility-buttons clearfix hidden-print">
	<li class="printButton"><a onclick="javascript:window.print();" href="#">PRINT</a></li>
	<li class="shareButton"><a onclick="javascript:showTemplate();" href="#">SHARE</a></li>
</ul>
</div>
	        </div>

           
           <div class="row">
               <div class="span12"></div><!-- End of span12 -->
           		<div id="home4">
               		<div class="home4content">
                        <h1>Merck is studying an investigational treatment through our Keynote Oncology Clinical Trials</h1>
                        <p>Our Keynote Oncology Clinical Trials are studying a way to treat cancer through immunotherapy – an approach that may help the body’s immune system fight cancer. The investigational immunotherapy used in the Keynote Oncology Clinical Trials is called pembrolizumab (MK-3475).</p>
               		</div>
           		</div>
            </div><!-- End of row -->    
        </header><!-- End of header -->

        <div class="container">
            <div class="row">
                <div class="span7">
                  <p>Pembrolizumab has been FDA-approved for use in some patients with advanced melanoma and certain patients with non-small cell lung cancer.</p>

                  <p>Since many clinical trials involve new drugs or test drugs in new ways, there are risks associated with participation. It is important that patients understand these risks before agreeing to participate. The possible benefits and risks should be discussed with a doctor.</p>

                  <h2>HOW PEMBROLIZUMAB WORKS</h2>

                  <p>Immunotherapy is a type of therapy that may help the body’s immune system attack cancer cells. The investigational immunotherapy being studied is called pembrolizumab. Pembrolizumab blocks the interaction of PD-1 with another protein called PD-L1, which is sometimes found on tumor cells. Blocking this interaction may help the immune system recognize certain tumors and attack them.</p>

              </div><!-- End of span6 -->
              <div class="span5" style="float:right;">
            	<div id="callout">

            		<p>Merck has investigational clinical trials under way or planned in more than 30 types of cancer. We are currently studying the following:</p>

            		<ul>
            			<li>Bladder Cancer</li>
            			<li>Breast Cancer</li>
            			<li>Gastric Cancer</li>
            			<li>Head and Neck Cancer</li>
            			<li>Hematology</li>
            			<li>Melanoma</li>
            			<li>Lung Cancer</li>
            			<li>Ovarian Cancer</li>
            			<li>Pediatric</li>
            			<li>Colorectal Cancer</li>
            			<li>Esophageal Cancer</li>
            			<li>As well as other types of cancer</li>
            		</ul>

            	</div>
              </div>
              <!-- End of span3 -->
            </div><!-- End of row -->


            <div id="clear_space"></div>
  
            <div class="row">
				<div class="span12">
				    <div class="ui-group">
				      <h3>Select cancer type below:</h3>
				      <div id="filters" class="button-group">
				        <button class="button is-checked" data-filter="*">show all</button>
				        <button class="button" data-filter=".bladder">bladder cancer</button>
				        <button class="button" data-filter=".breast">breast cancer</button>
					<button class="button" data-filter=".colorectal-carcinoma">colorectal carcinoma</button>
				        <button class="button" data-filter=".gastric">gastric cancer</button>
				        <button class="button" data-filter=".head-neck">head &amp; neck</button>
				        <button class="button" data-filter=".hodgkin">hodgkin lymphoma</button>
                        <button class="button" data-filter=".ovarian">ovarian cancer</button>
                        <button class="button" data-filter=".prostate">prostate cancer</button>
                      </div>
				    </div>
					<div class="grid">
					  <div class="grid-item head-neck" data-category="head-neck">
					  	<p class="tag">Head &amp; Neck</p>
					  	<img src="images/keynote-40.png" />
					  	<p><a href="3475-040.html" target="_blank">A PHASE III, UNBLINDED OPEN-LABEL, RANDOMIZED TRIAL OF MK-3475 (PEMBROLIZUMAB) VERSUS STANDARD TREATMENT IN SUBJECTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER (MK-3475 040)</a></p>
					  </div>
					  <div class="grid-item bladder" data-category="bladder">
					  	<p class="tag">Bladder Cancer</p>
					  	<img src="images/keynote-45.png" />
					  	<p><a href="3475-045.html" target="_blank">A PHASE III, UNBLINDED OPEN-LABEL, RANDOMIZED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERSUS PACLITAXEL, DOCETAXEL OR VINFLUNINE IN SUBJECTS WITH RECURRENT OR PROGRESSIVE METASTATIC BLADDER/UROTHELIAL CANCER (MK-3475 045)</a></p>
					  </div>
					  <div class="grid-item head-neck" data-category="head-neck">
					  	<p class="tag">Head &amp; Neck</p>
					  	<img src="images/keynote-48.png" />
					  	<p><a href="3475-048.html" target="_blank">A PHASE III, UNBLINDED, OPEN-LABEL, CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) IN FIRST-LINE TREATMENT OF RECURRENT/ METASTATIC HEAD AND NECK SQUAMOUS CELL CANCER (MK-3475 048)</a></p>
					  </div>
					  <div class="grid-item bladder" data-category="bladder">
					  	<p class="tag">Bladder Cancer</p>
					  	<img src="images/keynote-52.png" />
					  	<p><a href="3475-052.html" target="_blank">A PHASE II, UNBLINDED OPEN-LABEL, CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) IN SUBJECTS WITH ADVANCED/ UNRESECTABLE OR METASTATIC UROTHELIAL CANCER (MK-3475 052)</a></p>
					  </div>
					  <div class="grid-item bladder" data-category="bladder">
					  	<p class="tag">Bladder Cancer</p>
					  	<img src="images/keynote-57.png" />
					  	<p><a href="3475-057.html" target="_blank">A PHASE II, UNBLINDED OPEN-LABEL, CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN SUBJECTS WITH HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG) THERAPY (MK-3475 057)</a></p>
					  </div>                      
					  <div class="grid-item gastric" data-category="gastric">
					  	<p class="tag">Gastric Cancer</p>
					  	<img src="images/keynote-59.png" />
					  	<p><a href="3475-059.html" target="_blank">A PHASE II, UNBLINDED, OPEN-LABEL, CLINICAL TRIAL OF PEMBROLIZUMAB AS MONOTHERAPY AND IN COMBINATION WITH CISPLATIN+5-FLUOROURACIL IN SUBJECTS WITH RECURRENT OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (MK-3475 059)</a></p>
					  </div>
					  <div class="grid-item gastric" data-category="gastric">
					  	<p class="tag">Gastric Cancer</p>
					  	<img src="images/keynote-61.png" />
					  	<p><a href="3475-061.html" target="_blank">A PHASE III, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERSUS PACLITAXEL IN SUBJECTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA WHO PROGRESSED AFTER FIRST-LINE THERAPY WITH PLATINUM AND FLUOROPYRIMIDINE (MK-3475 061)</a></p>
					  </div>
					  <div class="grid-item gastric" data-category="gastric">
					  	<p class="tag">Gastric Cancer</p>
					  	<img src="images/keynote-62.png" />
					  	<p><a href="3475-062.html" target="_blank">A RANDOMIZED, ACTIVE-CONTROLLED, PARTIALLY BLINDED, BIOMARKER SELECT, PHASE III CLINICAL TRIALS OF MK-3475 (PEMBROLIZUMAB) AS MONOTHERAPY AND IN COMBINATION WITH CISPLATIN+5-FLUOROURACIL VERSUS PLACEBO+CISPLATIN+5-FLUOROUACIL AS FIRST-LINE TREATMENT IN SUBJECTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (MK-3475 062)</a></p>
					  </div>                      
					  <div class="grid-item breast" data-category="breast">
					  	<p class="tag">Breast Cancer</p>
					  	<img src="images/keynote-86.png" />
					  	<p><a href="3475-086.html" target="_blank">A PHASE II STUDY OF PEMBROLIZUMAB AS MONOTHERAPY FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC) (MK 3475-086)</a></p>
					  </div>
					  <div class="grid-item hodgkin" data-category="hodgkin">
					  	<p class="tag">Hodgkin Lymphoma</p>
					  	<img src="images/keynote-87.png" />
					  	<p><a href="3475-087.html" target="_blank">A PHASE II, UNBLINDED, OPEN-LABEL, CLINICAL TRIAL OF MK-3475 (PEMBROLIZUMAB) IN SUBJECTS WITH RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) (3475-087)</a></p>
					  </div>

					  <div class="grid-item ovarian" data-category="ovarian">
					  	<p class="tag">Ovarian Cancer</p>
					  	<img src="images/keynote-100.png" />
					  	<p><a href="3475-100.html" target="_blank" style="text-transform:uppercase;">A Phase II, Unblinded, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer (MK-3475 100)</a></p>
					  </div>

					  <div class="grid-item breast" data-category="breast">
					  	<p class="tag">Breast Cancer</p>
					  	<img src="images/keynote-119.png" />
					  	<p><a href="3475-119.html" target="_blank">A RANDOMIZED, PHASE III, OPEN-LABEL STUDY OF SINGLE AGENT PEMBROLIZUMAB (MK-3475) VERSUS SINGLE AGENT CHEMOTHERAPY PER PHYSICIAN’S CHOICE FOR METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) (MK 3475-119)</a></p>
					  </div>
                      <div class="grid-item head-neck" data-category="head-neck">
					  	<p class="tag">Head &amp; Neck</p>
					  	<img src="images/keynote-122.png" />
					  	<p><a href="3475-122.html" target="_blank">A TWO-ARM, OPEN-LABEL, RANDOMIZED PHASE II STUDY OF PEMBROLIZUMAB (MK-3475) MONOTHERAPY VERSUS STANDARD CHEMOTHERAPY IN PLATINUM PRE-TREATED, RECURRENT OR METASTATIC NASOPHARYNGEAL CANCER (NPC) (MK-3475 122)</a></p>
					  </div>

                      <div class="grid-item colorectal-carcinoma" data-category="colorectal-carcinoma">
					  	<p class="tag">Colorectal Carcinoma</p>
					  	<img src="images/keynote-177.png" />
					  	<p><a href="3475-177.html" target="_blank" style="text-transform:uppercase;"> PHASE III, UNBLINDED, OPEN-LABEL STUDY OF PEMBROLIZUMAB (MK-3475) VS. CHEMOTHERAPY IN MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) STAGE IV COLORECTAL CARCINOMA (MK-3475 177)</a></p>
					  </div>

                      <div class="grid-item prostate" data-category="prostate">
					  	<p class="tag">Prostate Cancer</p>
					  	<img src="images/keynote-199.png" />
					  	<p><a href="3475-199.html" target="_blank" style="text-transform:uppercase;">Phase II, Unblinded, Open-label, Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (MK-3475 199)</a></p>
					  </div>
					  <div class="grid-item bladder" data-category="bladder">
					  	<p class="tag">Bladder Cancer</p>
					  	<img src="images/keynote-361.png" />
					  	<p><a href="3475-361.html" target="_blank" style="text-transform:uppercase;">A Phase III, Randomized, Unblinded, Open-label, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475 361)</a></p>
					  </div>
					  <div class="grid-item prostate" data-category="prostate">
					  	<p class="tag">Prostate Cancer</p>
					  	<img src="images/keynote-365.png" />
					  	<p><a href="3475-365.html" target="_blank" style="text-transform:uppercase;">Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-3475 365)</a></p>
					  </div>
					</div>
            	</div>
            </div>        
        </div><!-- End of container -->
    	<div id="push"></div>
  </div>
  </div><!-- End of wrap -->
	<div id="footer" class="footer_container">
    	<div class="container">
            <footer>
                <ul class="muted unstyled inline">
                	<li><small>&copy; 2009-2016 Merck Sharp &amp; Dohme Corp., a subsidiary of <strong>Merck &amp; Co., Inc.</strong> All rights reserved.</small></li>
                    <li><a href="../../about/how-we-operate/privacy/home.html" target="_blank"><small>Privacy</small></a></li>
                    <li><a href="../../policy/terms-of-use/home.html" target="_blank"><small>Terms of Use</small></a></li>
                    <li class="pull-right">&nbsp;<a href="../../index.html" target="_blank"><img src="images/small_merck_logo.png" width="100" height="34" border="0" /></a></li>
                </ul>
            </footer>
			
			
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','../../../www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-45296711-2', 'merck.com');
  ga('send', 'pageview');

</script>

    	</div><!-- End of container -->
    </div><!-- End of footer_container -->
    
    <script src="../js/jquery.js" type="text/javascript"></script>
    <script src="../js/bootstrap.js" type="text/javascript"></script>
    <script src="../js/jquery.sticky.js" type="text/javascript"></script>
	<script src="../js/isotope.pkgd.min.js"></script>
	<script>
		$(window).load(function(){
		  $(".header_container").sticky();
		});
  	</script>
  	<script>
	$( document ).ready( function() {
		$('.grid').isotope({
		  // options
		  itemSelector: '.grid-item',
		  layoutMode:'fitRows'
		});
		$('#filters').on( 'click', 'button', function() {
		  var filterValue = $( this ).attr('data-filter');
		  // use filterFn if matches value
		  $('.grid').isotope({ filter: filterValue });
		});
		$('.button-group').each( function( i, buttonGroup ) {
		  var $buttonGroup = $( buttonGroup );
		  $buttonGroup.on( 'click', 'button', function() {
		    $buttonGroup.find('.is-checked').removeClass('is-checked');
		    $( this ).addClass('is-checked');
		  });
		});
	});
	</script>
            
  </body>

<!-- Mirrored from www.merck.com/clinical-trials/infographics/oncology.html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 18 Feb 2017 23:09:40 GMT -->
</html>
